5-羟色胺1A/2A受体基因多态性与SSRIs抗抑郁疗效的相关性研究
x

请在关注微信后,向客服人员索取文件

篇名: 5-羟色胺1A/2A受体基因多态性与SSRIs抗抑郁疗效的相关性研究
TITLE:
摘要: 目的:研究患者5-羟色胺1A/2A(5-HTR1A/2A)基因多态性与选择性5-羟色胺再摄取抑制剂(SSRI)类药物(SSRIs)抗抑郁疗效的相关性,为SSRIs的合理使用提供参考。方法:采用前瞻性研究方法,选取2016年10月-2017年10月内蒙古自治区人民医院精神专科符合入组标准的85例抑郁症住院患者,随机口服SSRIs帕罗西汀或舍曲林或艾司西酞普兰中的任意一种进行治疗,治疗周期为8周。以汉密尔顿焦虑量表(HAMD)评分计算所得患者治疗后的HAMD减分率为标准,分为有效组(HAMD减分率≥50%)和无效组(HAMD减分率<50%)。采用χ2检验分析两组患者5-HTR1A(rs6295)、5-HTR2A(rs6313、rs6311)的基因型分布和基因分布频率的差异,t检验比较有显著影响基因型对HAMD减分率的影响。结果:有效组患者45例,无效组患者40例,两组患者间民族、性别、年龄差异均无统计学意义(P>0.05)。两组患者5-HTR1A(rs6295)等位基因G、C的分布频率差异有统计学意义(χ2=13.75,P<0.001),基因型分布差异无统计学意义(χ2=4.72,P=0.09);5-HTR2A(rs6313)等位基因G、A和5-HTR2A(rs6311)等位基因C、T的分布频率差异均有统计学意义(χ2=15.20、15.20,P<0.001),基因型分布差异也均有统计学意义(χ2=23.68、23.68,P<0.001)。5-HTR2A(rs6313)G/A、G/G、A/A 3种基因型患者间HAMD减分率差异无统计学意义(P>0.05)。5-HTR2A(rs6311)T/T与C/C、T/T与C/T基因型患者间HAMD减分率差异无统计学意义(P>0.05),仅C/C基因型患者HAMD减分率明显高于C/T基因型患者(P=0.02)。结论:5-HTR2A(rs6313、rs6311)基因多态性可能与SSRIs治疗抑郁症的临床疗效有关,其中5-HTR2A(rs6311)C/C基因型有希望作为SSRIs治疗抑郁症时判别疗效的预测因子。
ABSTRACT: OBJECTIVE: To study the association of 5-HTR1A/2A receptor gene polymorphism with antidepressant efficacy of selective 5-serotonin reuptake inhibitors (SSRIs), and to provide reference for rational use of SSRIs. METHODS: In perspective study, 85 depressive inpatients met inclusion criteria were selected from Inner Mongolia Autonomous Region People’s Hospital during Oct. 2016-Oct. 2017. They were randomly given one kind of SSRIs as paroxetine, sertraline or escitalopram oxalate, for 8 weeks. They were divided into valid group (HAMD reduction rate≥50%) and invalid group (HAMD reduction rate<50%) according to HAMD reduction rate calculated by HAMD score after treatment. Difference of genotype distribution and genotype distribution frequency of 5-HTR1A (rs6295) and 5-HTR2A (rs6313, rs6311) were analyzed by χ2-test in 2 groups. t-test comparison significantly influenced the effects of genotype on HAMD reduction rate. RESULTS: There were 45 patients in valid group and 40 patients in invalid group; there was no statistical significance in the difference in nationality, gender or age between 2 groups (P>0.05). There was statistical significance in the distribution frequency of 5-HTR1A(rs6295) allele G and C between 2 groups (χ2=13.75,P<0.001); there was no statistical significance in genotype distribution (χ2=4.72,P=0.09). There was statistical significance in the distribution frequency of 5-HTR2A(rs6313) allele G and A with 5-HTR2A(rs6311) allele C and T (χ2=15.20, 15.20, P<0.001). There was statistical significance in difference of genotype distribution (χ2=23.68, 23.68, P<0.001). There was no statistical significance in HAMD reduction rate among 5-HTR2A(rs6313)G/A, G/G, A/A genotypes (P>0.05). There was no statistical significance in HAMD reduction rate between 5-HTR2A(rs6311)T/T genotype and C/C genotype, between 5-HTR2A(rs6311)T/T genotype and C/T genotype (P>0.05). HAMD reduction rate of C/C genotype was significantly higher than that of C/T genotype (P=0.02). CONCLUSIONS: 5-HTR2A (rs6313, rs6311) gene polymorphism may be associated with clinical efficacy of SSRIs for depression. 5-HTR2A(rs6311) C/C genotype is hopeful as a efficacy predictor of SSRIs in the treatment of depression.
期刊: 2018年第29卷第17期
作者: 斯日古楞,刘相辰,杨帆,杨宏昕
AUTHORS: Siriguleng,LIU Xiangchen,YANG Fan,YANG Hongxin
关键字: 抑郁症;选择性5-羟色胺再摄取抑制剂;5-羟色胺1A 受体;5-羟色胺2A受体;基因多态性
KEYWORDS: Depression; Selective 5-serotonin reuptake inhibitor; 5-HTR1A receptor; 5-HTR2A receptor; Gene polymorphism
阅读数: 685 次
本月下载数: 12 次

* 注:未经本站明确许可,任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作!